

Roadmap to Combination Therapies for Alzheimer's Disease
An Alzheimer's Disease Expert Retreat

Grand Hyatt Washington
1000 H Street, NW
Washington, DC 20001

May 28-30, 2013

Combination therapy development has been successful in other life-threatening diseases in part because collaborative approaches were established to identify necessary pathways and tools that enabled more efficient trials. Our goal is to recommend a roadmap that spurs combination therapy development in Alzheimer's disease (AD).

DAY 1 : Establishing the Scientific Consensus

9:00-9:30 a.m.	Registration and Breakfast
9:30-10:00 am	Welcome Dan Perry, ACT-AD Diane Stephenson, Ph.D., Critical Path Institute
10:00-10:45 a.m.	Scientific Rationale for Pursuing Multiple Targets John Trojanowski, M.D., Ph.D., University of Pennsylvania
10:45-11:00 a.m.	Break
11:00-12:00 p.m.	Advancing Different Targets through Development Stages Panel Chair: Reisa Sperling, M.D., MMsc, Harvard Brigham and Women's Rusty Katz, M.D., U.S. Food and Drug Administration Steven Potkin, M.D., UC Irvine Don Berry, Ph.D., Berry Consultants
12:00-12:30 a.m.	Q& A
12:30-1:00 p.m.	Lunch
1:00-3:30 p.m.	Concurrent Working Group Sessions Group 1- Viable Targets for Immediate Exploitation in Combination Co-chairs: Diane Stephenson, Ph.D. (Critical Path Institute), Val Gribkoff, Ph.D. (Elan) Group 2- Enabling Combinations through Modeling and Simulation Co-chairs: Debra Hanna, Ph.D. (Critical Path Institute), Yaning Wang, Ph.D. (U.S. Food and Drug Administration)
3:30-5:00 p.m.	Working Group Reports and Discussion

DAY 2: Identifying the Partnerships

- 8:30-9:00 a.m. **Registration and Breakfast**
- 9:00-9:30 a.m. **Welcome and Day 1 Recap**
Maria Carrillo, Ph.D., Alzheimer's Association
- 9:30-10:00 a.m. **Structuring a Partnership for Combination Development**
Debra Hanna, Ph.D., Critical Path Institute
- 10:00-10:15 a.m. **Q& A**
- 10:15-11:15 a.m. **Effective Partnerships that Foster Collaboration**
Panel Chair: David Dilts, Ph.D., MBA, CMA, Dilts Partners
Debra Hanna, Ph.D., Critical Path Institute
Chas Bountra, Ph.D., University of Oxford
- 11:15-11:30 a.m. **Q& A**
- 11:30-12:00 p.m. **Lunch**
- 12:00-3:00 p.m. **Concurrent Working Group Sessions**
Group 3- Opportunities to Pursue Through Consortia and Funding
Co-chairs: Heather Snyder, Ph.D. (Alzheimer's Association),
Enchi Liu, Ph.D. (Janssen)
Group 4- Data Sharing and Forming an Effective Partnership to
Enable Combination Development
Co-chairs: Cynthia Bens (ACT-AD), Tony Ware, M.D. (Lilly)
- 3:00-5:00 p.m. **Working Group Reports and Discussion**

DAY 3

- 8:30-9:00 a.m. **Breakfast**
- 9:00-9:30 a.m. **Welcome and Day 2 Recap**
Diane Stephenson, Ph.D., Critical Path Institute
- 9:30-10:30 a.m. **Presentation of Recommendations for Roadmap**
Working Group Co-chairs
- 10:30-11:30 **Q& A**
- 11:30-12:00 p.m. **Wrap up and Next Steps**
Dan Perry, ACT-AD